Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB. Saukkonen T, et al. Among authors: williams rm. J Clin Endocrinol Metab. 2004 Sep;89(9):4634-41. doi: 10.1210/jc.2004-0243. J Clin Endocrinol Metab. 2004. PMID: 15356074 Clinical Trial.
Increasing urine albumin excretion is associated with growth hormone hypersecretion and reduced clearance of insulin in adolescents and young adults with type 1 diabetes: the Oxford Regional Prospective Study.
Amin R, Williams RM, Frystyk J, Umpleby M, Matthews D, Orskov H, Dalton RN, Dunger DB. Amin R, et al. Among authors: williams rm. Clin Endocrinol (Oxf). 2005 Feb;62(2):137-44. doi: 10.1111/j.1365-2265.2005.02185.x. Clin Endocrinol (Oxf). 2005. PMID: 15670188
Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
Williams RM, Yuen K, White D, Mallard B, Dalton RN, Acerini CL, Dunger DB. Williams RM, et al. Clin Endocrinol (Oxf). 2006 Oct;65(4):439-45. doi: 10.1111/j.1365-2265.2006.02600.x. Clin Endocrinol (Oxf). 2006. PMID: 16984235 Clinical Trial.
IGF-I treatment of insulin resistance.
McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. McDonald A, et al. Among authors: williams rm. Eur J Endocrinol. 2007 Aug;157 Suppl 1:S51-6. doi: 10.1530/EJE-07-0271. Eur J Endocrinol. 2007. PMID: 17785698 Review.
Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Williams RM, McDonald A, O'Savage M, Dunger DB. Williams RM, et al. Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):311-24. doi: 10.1517/17425255.4.3.311. Expert Opin Drug Metab Toxicol. 2008. PMID: 18363546 Review.
Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.
Regan FM, Williams RM, McDonald A, Umpleby AM, Acerini CL, O'Rahilly S, Hovorka R, Semple RK, Dunger DB. Regan FM, et al. Among authors: williams rm. J Clin Endocrinol Metab. 2010 May;95(5):2113-22. doi: 10.1210/jc.2009-2088. Epub 2010 Mar 16. J Clin Endocrinol Metab. 2010. PMID: 20233784
824 results